The "oil well analogy" as a comprehensive interpretation of factors leading to muscle injury and wasting

Ultrastructural Pathology

Volumn 30, Issue 4, 2006, Pages 247-252

  Orozco Levi, Mauricio ^a,b   Lloreta, Josep ^a   Gea, Joaquim ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Apoptosis; Cachexia; Chronic obstructive pulmonary disease (COPD); Muscle; Myopathy; Oxidative stress

Indexed keywords

APOPTOSIS; AUTOPHAGY; BIOSYNTHESIS; BREATHING MUSCLE; CACHEXIA; CATABOLISM; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFOCAL MICROSCOPY; DIETARY INTAKE; ENERGY EXPENDITURE; ENERGY RESOURCE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE INJURY; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGENERATION; REVIEW; RISK FACTOR; SKELETAL MUSCLE;

HUMANS; METAPHOR; MODELS, BIOLOGICAL; MUSCULAR ATROPHY; MUSCULAR DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33748698021     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.1080/01913120600820146     Document Type: Review

References (37)

1. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-1418.
2. Hodge S, Hodge G, Holmes M, Flower R, et al. Interleukin-4 and tumour necrosis factor-alpha inhibit transforming growth factor-beta production in a human bronchial epithelial cell line: possible relevance to inflammatory mechanisms in chronic obstructive pulmonary disease. Respirology. 2001;6:205-211.
3. Rabinovich RA, Ardite E, Troosters T, et al. Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1114-1118.
4. Maltais F, Simard AA, Simard C, Jobin J, Desgagnes P, LeBlanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med. 1996;153:288-293.
5. Gea J, Orozco-Levi M, Barreiro E, et al. Structural and functional changes in the skeletal muscles of COPD patients: the "compartments" theory. Monaldi Arch Chest Dis. 2001;56:214-224.
6. Killian KJ, Leblanc P, Martin DH, et al. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rec Respir Dis. 1992;146:935-940.
7. Hamilton N, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med. 1995;152:2021-2031
8. Speizer FE. The rise in chronic obstructive pulmonary disease: overview and summary. Am Rev Respir Dis. 1989;140:S106-S107.
9. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
10. Morrison WL, Gibson JN, Scrimgeour C, et al. Muscle wasting in emphysema. Clin Sci. 1988;75:415-420.
11. Barreiro E, Gea J, Corominas JM, et al. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2003;29:771-778.
12. Barreiro E, de la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:1116-1124.
13. Dean RT, Fu SL, Stocker R, et al. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J. 1997;324:1-18.
14. Langen RC, Schols AM, Kelders MC, et al. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol. 2002;283:C714-C721.
15. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 1996;15:1753-1765.
16. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.
17. Aid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1414-1418.
18. Gosker HR, Kubat B, Schaart G, et al. Myopathologic features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;22:280-285.
19. Dimopoulou I, Ilias I, Mastorakos G, et al. Effects of severity of chronic obstructive pulmonaryu disease on thyroid function. Metabolism. 2001;50:1397-1401.
20. Kamishke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11:41-45.
21. Orozco-Levi M, Lloreta J, Minguella J, et al. Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1734-1739.
22. Orozco-Levi M, Coronell C, Ramírez-Sarmiento A, et al. Injury of peripheral muscles in susceptible smokers with chronic obstructive pulmonary disease. Eur Respir J. 2004;24:suppl. 48, 217s.
23. Fridén J, Sjöstrom M, Ekblom B. Myofibrillar injury following intense eccentric exercise in humans. Int J Sports Med. 1983;4:170-176.
24. Serres I, Gautier V, Varray A, et al. Impaired skeletal muscle endurance related to physical activity and altered lung function in COPD patients. Chest. 1998;113:900-905.
25. Armstrong RB. Initial events in exercise-induced muscle injury. Med Sci Sports Exerc. 1990;22:429-435.
26. MacIntyre DL, Reid WD, McKenzie DC. Delayed muscle soreness: the inflammatory response to muscle injury and its clinical implications. Sports Med. 1995;20:24-40.
27. Lemasters JJ, Qian T, He L, et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal. 2002;4:769-781.
28. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome in muscle atrophy? Curr Opin Clin Nutr Metab Care. 2001;4:183-190.
29. Llovera M, Carbo N, Lopez-Soriano J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998;133(1):83-87.
30. Tsirigotis M, Zhang M, Chiu RK, et al. Sensitivity of mammalian cells expressing mutant ubiquitin to protein-damaging agents. J Biol Chem. 2001;276(49):46073-46078.
31. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet. 1996;30:405-439.
32. Mortimore GE, Poso AR. Intracellular protein catabolism and its control during nutrient deprivation and supply. Annu Rev Nutr. 1987;7:539-564.
33. Mizushima N, Ohsumi Y, Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct. 2002;27:421-429.
34. Marino G, Lopez-Otin C. Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell Mol Life Sci. 2004;61:1439-1454.
35. Blommart EFC, Luiken JJFP, Meijer AJ. Autophagic proteolysis: control and specificity. Histochem J. 1997;29:365-385.
36. Rodriguez-Enriquez S, He L, Lemasters JJ. Role of mitochondrial permeability transition pores in mitochondrial autophagy. Int J Biochem Cell Biol. 2004;36:2463-2472.
37. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun. 2003;304:463-470.